CAR T therapy is a promising new treatment for cancer, and it is likely to continue to evolve in the years to come. These are just a few of the recent advancements in CAR T therapy treatment.

The development of new CAR constructs

The first generation of CAR T cells were relatively simple, with a single-chain variable fragment (scFv) that recognized a tumor-specific antigen. However, these CAR T cells were not very specific and could often attack healthy cells. In recent years, researchers have developed more sophisticated CAR constructs that are more specific for tumor cells. These CAR constructs often have multiple scFvs that recognize different tumor-specific antigens. This increased specificity helps to reduce the risk of CAR T cells attacking healthy cells.

The use of cytokine-armed CAR T cells

Cytokines are proteins that help to activate the immune system. Cytokine-armed CAR T cells are CAR T cells that have been engineered to secrete cytokines. These cytokines help to activate the CAR T cells and make them more effective at killing tumor cells. In addition, cytokines can also help to recruit other immune cells to the tumor site. This can help to create a more effective immune response against the tumor.

The use of CAR T cells in combination with other therapies

CAR T cells can be used in combination with other therapies, such as chemotherapy and radiation therapy. This combination therapy has been shown to be more effective than CAR T cells alone. Chemotherapy and radiation therapy can help to shrink the tumor and make it easier for CAR T cells to reach the tumor cells. Additionally, chemotherapy and radiation therapy can help to kill any tumor cells that the CAR T cells do not kill.

The development of CAR T cells for solid tumors

CAR T cells have been primarily used to treat hematological malignancies, such as leukemia and lymphoma. However, researchers are now developing CAR T cells for solid tumors. This is a challenging task, as solid tumors are more heterogeneous than hematological malignancies and are more difficult to target with CAR T cells. However, there have been some promising results in recent clinical trials. For example, a clinical trial of CAR T cells targeting the MUC1 antigen in breast cancer showed that the CAR T cells were able to shrink tumors and improve survival.


CAR T therapy is a promising new treatment for cancer. It has the potential to be a curative treatment for some types of cancer. However, there are still some challenges that need to be addressed, such as the development of CAR T cells for solid tumors and the risk of side effects.

CAR-T cell therapy in Israel
CAR-T for Leukemia and Lymphoma in Israel
CAR-T for Myeloma in Israel
CAR-T cell therapy for leukemia and non-Hodgkin's lymphoma (NHL) in Europe
CAR-T cell therapy for Multiple Myeloma patients in Europe